Scholar Rock Holding Corporation (SRRK)

NASDAQ: SRRK · IEX Real-Time Price · USD
5.18
-0.81 (-13.52%)
May 18, 2022 12:22 PM EDT - Market open
Market Cap182.86M
Revenue (ttm)47.30M
Net Income (ttm)-112.08M
Shares Out35.30M
EPS (ttm)-3.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume157,533
Open5.80
Previous Close5.99
Day's Range5.02 - 5.87
52-Week Range5.02 - 44.95
Beta0.24
AnalystsBuy
Price Target45.29 (+774.3%)
Earnings DateMay 12, 2022

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-P...

IndustryBiotechnology
IPO DateMay 24, 2018
CEONagesh Mahanthappa
Employees145
Stock ExchangeNASDAQ
Ticker SymbolSRRK
Full Company Profile

Financial Performance

In 2021, SRRK's revenue was $18.82 million, an increase of 22.16% compared to the previous year's $15.40 million. Losses were -$131.80 million, 52.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is 45.29, which is an increase of 774.32% from the latest price.

Price Target
$45.29
(774.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Scholar Rock Shares Jumps On Updating Strategic Priorities

Scholar Rock Holding Corp (NASDAQ: SRRK) plans to reduce its overall headcount by 25%, and its Chief Medical Officer Yung Chyung will step down by the end of June.  "Parting with employees who have dedi...

23 hours ago - Benzinga

Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fun...

1 day ago - Business Wire

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 20...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

3 weeks ago - Business Wire

Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?

Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving highe...

1 month ago - Zacks Investment Research

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the Am...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced that it is presenting encore data in an e-poster at the American Academy of Neurology (AAN) 2022 Annual Meeting.

1 month ago - Business Wire

Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) C...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a poster presentation at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 13 - 16.

2 months ago - Business Wire

Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for t...

2 months ago - Zacks Investment Research

Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

2 months ago - Business Wire

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q4 Earnings Expected to Decline

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Scholar Rock to Present at Cowen's 42nd Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

2 months ago - Business Wire

Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced a presentation at the 2nd Annual TGFβ for Immuno-Oncology Drug Development Summit (January 25-27, 2022).

3 months ago - Business Wire

Scholar Rock Provides Corporate Update and Highlights Priorities for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

4 months ago - Business Wire

Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

4 months ago - Business Wire

Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients wi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

5 months ago - Business Wire

Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combinati...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today presented initial clinical data from Part A of its DRAGON Phase 1 proof-of-concept trial at the SITC Annual Meeting.

6 months ago - Business Wire

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...

6 months ago - Zacks Investment Research

Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

6 months ago - Business Wire

Scholar Rock to Present at Upcoming Healthcare Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

6 months ago - Business Wire

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q3 Earnings Expected to Decline

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces an e-poster presentation of clinical results from the TOPAZ Phase 2 trial at the 25th World Congress of Neurology (WCN).

7 months ago - Business Wire

Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a late breaker poster presentation as part of the 50th Child Neurology Society (CNS) Annual Meeting, occurring 9/29 - 10/2.

7 months ago - Business Wire

Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that the USPTO issued U.S. Patent No. 11,130,803, with projected expiry of May 2040, providing product protection for SRK-181.

7 months ago - Business Wire

Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock is announcing two poster presentations as part of the World Muscle Society (WMS) Virtual Congress taking place September 20-24, 2021.

7 months ago - Business Wire

Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...

7 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation ...

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK)...

9 months ago - Newsfile Corp